Saniona AB - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Saniona AB - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Saniona AB - Product Pipeline Review - 2016', provides an overview of the Saniona AB's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Saniona AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Saniona AB
- The report provides overview of Saniona AB including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Saniona AB's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Saniona AB's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Saniona AB's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Saniona AB
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Saniona AB's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Saniona AB Snapshot 6
Saniona AB Overview 6
Key Information 6
Key Facts 6
Saniona AB - Research and Development Overview 7
Key Therapeutic Areas 7
Saniona AB - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Saniona AB - Pipeline Products Glance 15
Saniona AB - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Saniona AB - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Saniona AB - Drug Profiles 19
(metoprolol + tesofensine) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NS-2359 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
tesofensine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AN-721 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AN-788 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AN-346 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AN-470 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AN-761 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NS-9283 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Agonize GABAA Alpha 2 and Alpha 3 for Neuropathic Pain 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Activate TREK for Pain 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Block TREK for Depression 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Inhibit Monoamine Reuptake for Pain 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Saniona AB - Pipeline Analysis 44
Saniona AB - Pipeline Products by Target 44
Saniona AB - Pipeline Products by Route of Administration 46
Saniona AB - Pipeline Products by Molecule Type 47
Saniona AB - Pipeline Products by Mechanism of Action 48
Saniona AB - Recent Pipeline Updates 50
Saniona AB - Dormant Projects 51
Saniona AB - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
NS-2359 52
tesofensine 52
Saniona AB - Locations And Subsidiaries 53
Head Office 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Saniona AB, Key Information 6
Saniona AB, Key Facts 6
Saniona AB - Pipeline by Indication, 2016 9
Saniona AB - Pipeline by Stage of Development, 2016 10
Saniona AB - Monotherapy Products in Pipeline, 2016 11
Saniona AB - Combination Treatment Modalities in Pipeline, 2016 12
Saniona AB - Out-Licensed Products in Pipeline, 2016 13
Saniona AB - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Saniona AB - Phase II, 2016 15
Saniona AB - Phase I, 2016 16
Saniona AB - Preclinical, 2016 17
Saniona AB - Discovery, 2016 18
Saniona AB - Pipeline by Target, 2016 45
Saniona AB - Pipeline by Route of Administration, 2016 46
Saniona AB - Pipeline by Molecule Type, 2016 47
Saniona AB - Pipeline Products by Mechanism of Action, 2016 49
Saniona AB - Recent Pipeline Updates, 2016 50
Saniona AB - Dormant Developmental Projects,2016 51
Saniona AB - Discontinued Pipeline Products, 2016 52